Reserve ICDs (implantable defibrillators) for sickest patients, says study
This article was originally published in Clinica
The latest in a series of major trials examining the use of implantable defibrillators (ICDs) for treating life-threatening irregular heartbeats has suggested the devices should be used on only the oldest and sickest patients. Although the researchers were surprised at the high number of patients not suitable for ICDs, the study does add support to previous studies showing that patients at low risk may not be appropriate candidates for the expensive devices.
You may also be interested in...
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.